Royal Bank of Canada Has Lowered Expectations for uniQure (NASDAQ:QURE) Stock Price

uniQure (NASDAQ:QURE) had its price objective decreased by Royal Bank of Canada from $16.00 to $14.00 in a research report report published on Wednesday,Benzinga reports. Royal Bank of Canada currently has an outperform rating on the biotechnology company’s stock.

Several other equities research analysts have also recently weighed in on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $28.00 price objective on shares of uniQure in a research report on Wednesday. Raymond James reiterated an “outperform” rating and set a $20.00 price target on shares of uniQure in a report on Thursday, October 10th. The Goldman Sachs Group boosted their price objective on uniQure from $6.00 to $10.00 and gave the company a “neutral” rating in a research note on Friday, August 2nd. StockNews.com raised uniQure to a “sell” rating in a research note on Thursday, October 17th. Finally, HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of uniQure in a research note on Tuesday, August 20th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $17.00.

uniQure Trading Up 4.8 %

NASDAQ QURE opened at $7.79 on Wednesday. The firm has a market capitalization of $379.71 million, a PE ratio of -1.57 and a beta of 0.90. The business’s 50-day moving average price is $5.77 and its two-hundred day moving average price is $5.83. The company has a current ratio of 6.51, a quick ratio of 7.36 and a debt-to-equity ratio of 0.92. uniQure has a 12 month low of $3.73 and a 12 month high of $11.35.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The business had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $2.73 million. On average, analysts expect that uniQure will post -4.1 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in QURE. abrdn plc increased its holdings in shares of uniQure by 381.7% during the third quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock valued at $9,510,000 after acquiring an additional 1,528,581 shares in the last quarter. Vanguard Group Inc. grew its position in uniQure by 11.4% in the 1st quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock valued at $5,577,000 after purchasing an additional 109,740 shares during the period. Privium Fund Management B.V. increased its stake in uniQure by 16.3% during the 3rd quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock valued at $3,672,000 after purchasing an additional 104,500 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in uniQure by 4.3% during the first quarter. BNP Paribas Financial Markets now owns 736,724 shares of the biotechnology company’s stock worth $3,831,000 after buying an additional 30,054 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its stake in shares of uniQure by 133.1% in the first quarter. Acadian Asset Management LLC now owns 613,490 shares of the biotechnology company’s stock valued at $3,189,000 after buying an additional 350,291 shares in the last quarter. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.